Vigencell, a company specializing in immuno-cell therapies, announced on the 8th that it has successfully completed Cohort 2 of the clinical trial for "VT-Tri(1)-A," an acute myeloid leukemia (AML) treatment, and has initiated the final phase of its clinical trial, Cohort 3.

VT-Tri(1)-A targets multiple common antigens for the treatment of AML. Cohort 2, which began recruiting patients in September last year, was recently completed.

As with Cohort 1, no significant adverse reactions or dose-limiting toxicities (DLT) were observed in all patients treated in Cohort 2. In Cohort 3, the number of treatments per patient will increase to four, with the trial being conducted at seven institutions, including Seoul St. Mary's Hospital.

The VT-Tri(1)-A is based on the ViTier platform, an antigen-specific killer T-cell therapy. From 2007 to 2013, it was tested in a researcher-led trial that targeted a single WT1 tumor antigen (WT1-CTL), where it demonstrated a 71% two-year relapse-free survival rate and 0% recurrence, confirming both its safety and efficacy.

In Phase 1, the treatment has been further developed into VT-Tri(1)-A, which simultaneously targets three common tumor antigens (WT1, Survivin, TERT) to combat the immune evasion mechanisms of cancer cells.

Vigencell's Head of Development, Son Hyun-jung, stated, "We are pleased to begin enrolling patients for Cohort 3, having seen no major adverse events or unusual findings in Cohort 2. We will continue working through the rest of Phase 1 and beyond to provide a new treatment option for patients with acute myeloid leukemia."